Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes

Abstract

BackgroundMyelodysplastic syndromes (MDSs) are a very heterogeneous group of myeloid disorders with high prevalence and risk of developing acute myeloid leukemia. The more accurate risk stratification can provide a better guidance of treatment. The platelet–large cell ratio (P-LCR) is a parameter reported in complete blood cell count tests, and was associated with many diseases, but its role in MDS is not clear.PurposeThis study aims to explore the impact of the P-LCR on the prognosis of patients with MDS, which is of great significance for clinical treatment.MethodsIn the retrospective study, 122 newly diagnosed MDS patients were enrolled. We used the bioinformatics tool X-tile to define a P-LCR threshold of 36.7% to predict prognosis. Patients were divided into P-LCRlow and P-LCRhigh groups, and their characteristics were compared between the two groups.ResultsResults show that the P-LCRlow was associated with worse overall survival (OS) than the P-LCRhigh patients (median OS, 18.53 months versus 25.77 months, p=0.0057), but there were no statistical differences in progression-free survival (PFS) between the two groups (p=0.2001). The results of univariate and multivariate Cox proportional hazard analyses adjusted for gender, bone marrow blast level, platelet count, and International Prognostic Scoring System scores showed that the P-LCR was useful in the evaluation of PFS [hazard ratio (HR) 0.212, 95%CI 0.064–0.702, p=0.011] and OS of MDS (HR 0.464, 95%CI 0.284–0.757, p=0.002).ConclusionThis study is the first report showing that the P-LCR would be a simple and immediately available biomarker for predicting the prognosis of MDS.

The role of platelet large cell ratio in determining mortality in COVID-19 patients

“…[20] Also in another study, it is shown that P-LCR can be used as a prognostic parameter in myelodysplastic syndromes (MDS) patients as survival time was shorter especially in patients with low P-LCR. [21] Based on our results, we suggest that P-LCR may prove to be as useful as already established hematologic parameters in patients with a risk of cytokine storm, with the additional advantages of being an inexpensive and practical potential prognostic parameter.…”

“…Also in another study, it is shown that P-LCR can be used as a prognostic parameter in myelodysplastic syndromes (MDS) patients as survival time was shorter especially in patients with low P-LCR. [ 21 ]…”

The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term

“…We reported significantly higher postpartum P LCR in treated thrombophilia patients than in normal patients. Generally, the platelet‐large cell ratio (P‐LCR) increased with age, 38 but in the case of postpartum patients, a higher value of P LCR can be interpreted as the presence of a high percentage of new platelets characterized by a greater size, 39 since young platelets are larger and more active than mature cells, 40 and contain greater amounts of thromboxane A1 and beta‐thromboglobulin 41,42 . This means that labor triggered the release of more numerous young platelets and an increase in P‐LCR, but only in thrombophilia patients.…”

Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers

“…In link with this observation, Chen et al recently identified the platelet-large ratio (P-LCR), the percentage of platelets larger than 12 fL, as a prognostic factor in MDS in uni- and multivariate analyses. A low P-LCR fraction was associated with a decreased overall survival in a cohort of 122 MDS patients [ 20 ]. Ravalet et al identified PDW on the DxH 800 as a parameter predictive of MDSs [ 12 ].…”